Prevalence of the eosinophilic phenotype among severe asthma patients

Trial Identifier: D2287R00140
Sponsor: AstraZeneca
NCTID:: NCT03931954
Start Date: May 2019
Primary Completion Date: November 2020
Study Completion Date: November 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ARGENTINA BUENOS AIRES, ARGENTINA
ARGENTINA ROSARIO, ARGENTINA
CHILE CURICO, CHILE
COLOMBIA BARRANQUILLA, COLOMBIA
COLOMBIA BOGOTA, COLOMBIA
COLOMBIA BUCARAMANGA, COLOMBIA
COLOMBIA PEREIRA, COLOMBIA
COSTA RICA SAN JOSE, COSTA RICA
MEXICO GUADALAJARA, MEXICO
MEXICO MERIDA, MEXICO
MEXICO PUEBLA, MEXICO
MEXICO SAN JUAN DEL RIO, MEXICO
MEXICO VILLAHERMOSA, MEXICO
Saudi Arabia Dammam, Saudi Arabia
Saudi Arabia Riyadh, Saudi Arabia
Saudi Arabia Riyadh, Saudi Arabia, 111511